Advertisement
PTGX vs SRRK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Buy and SRRK is a Hold.
PTGX's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for PTGX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 18 of the 22 cases the stock moved higher. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 58 cases where PTGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTGX advanced for three days, in 231 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
PTGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PTGX as a result. In 67 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for PTGX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 35 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
PTGX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. PTGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.153) is normal, around the industry mean (3.498). PTGX has a moderately high P/E Ratio (108.230) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (34.130) is also within normal values, averaging (440.869).
Momentum Indicator for SRRK turns positive, indicating new upward trend
SRRK saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 71 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SRRK just turned positive on October 21, 2026. Looking at past instances where SRRK's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
Following a +13.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRRK advanced for three days, in 228 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for SRRK moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 54 cases where SRRK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
SRRK moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for SRRK moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
SRRK broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRRK entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. SRRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.525) is normal, around the industry mean (3.498). P/E Ratio (-14.181) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PTGX | SRRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 60 | |
SMR RATING 1..100 | 59 | 99 | |
PRICE GROWTH RATING 1..100 | 45 | 43 | |
P/E GROWTH RATING 1..100 | 67 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRRK's Valuation (79) in the Biotechnology industry is in the same range as PTGX (97). This means that SRRK’s stock grew similarly to PTGX’s over the last 12 months.
PTGX's Profit vs Risk Rating (5) in the Biotechnology industry is somewhat better than the same rating for SRRK (60). This means that PTGX’s stock grew somewhat faster than SRRK’s over the last 12 months.
PTGX's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for SRRK (99). This means that PTGX’s stock grew somewhat faster than SRRK’s over the last 12 months.
SRRK's Price Growth Rating (43) in the Biotechnology industry is in the same range as PTGX (45). This means that SRRK’s stock grew similarly to PTGX’s over the last 12 months.
SRRK's P/E Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for PTGX (67). This means that SRRK’s stock grew somewhat faster than PTGX’s over the last 12 months.
| PTGX | SRRK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 84% |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 75% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 78% |
| Advances ODDS (%) | 2 days ago 76% | 3 days ago 80% |
| Declines ODDS (%) | 6 days ago 76% | 1 day ago 87% |
| BollingerBands ODDS (%) | 1 day ago 72% | 1 day ago 89% |
| Aroon ODDS (%) | N/A | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PTGX’s FA Score shows that 1 FA rating(s) are green while SRRK’s FA Score has 0 green FA rating(s).
- PTGX’s FA Score: 1 green, 4 red.
- SRRK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PTGX’s TA Score shows that 4 TA indicator(s) are bullish while SRRK’s TA Score has 3 bullish TA indicator(s).
- PTGX’s TA Score: 4 bullish, 4 bearish.
- SRRK’s TA Score: 3 bullish, 7 bearish.
Price Growth
PTGX (@Biotechnology) experienced а -5.94% price change this week, while SRRK (@Biotechnology) price change was +1.11% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
PTGX is expected to report earnings on Mar 02, 2027.
SRRK is expected to report earnings on Mar 09, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PTGX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with MGTX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then MGTX could also see price increases.
| Ticker / NAME | Correlation To PTGX | 1D Price Change % | ||
|---|---|---|---|---|
| PTGX | 100% | -1.03% | ||
| MGTX - PTGX | 51% Loosely correlated | +0.62% | ||
| DYN - PTGX | 49% Loosely correlated | +0.39% | ||
| DNTH - PTGX | 47% Loosely correlated | +0.55% | ||
| ARQT - PTGX | 46% Loosely correlated | +3.63% | ||
| IMVT - PTGX | 46% Loosely correlated | +3.72% | ||
More | ||||
SRRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SRRK has been loosely correlated with RYTM. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SRRK jumps, then RYTM could also see price increases.
| Ticker / NAME | Correlation To SRRK | 1D Price Change % | ||
|---|---|---|---|---|
| SRRK | 100% | -2.92% | ||
| RYTM - SRRK | 48% Loosely correlated | -1.57% | ||
| PTGX - SRRK | 44% Loosely correlated | -1.03% | ||
| VERA - SRRK | 43% Loosely correlated | +1.50% | ||
| ARVN - SRRK | 42% Loosely correlated | -0.14% | ||
| CGON - SRRK | 41% Loosely correlated | -0.04% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HIMZ | 11.32 | 1.68 | +17.43% |
| Defiance Daily Target 2X Long HIMS ETF (HIMZ) | |||
| SLYG | 111.61 | 1.08 | +0.98% |
| State Street SPDR S&P 600 Small Cap Growth ETF (SLYG) | |||
| SPXD | 30.65 | 0.18 | +0.61% |
| Xtrackers S&P 500 Diversified Sector Weight ETF (SPXD) | |||
| BKHY | 45.77 | 0.09 | +0.20% |
| BNY Mellon High Yield ETF (BKHY) | |||
| KIE | 65.70 | -0.13 | -0.20% |
| State Street SPDR S&P Insurance ETF (KIE) | |||